ESC Professional Premium Access

Use of emgliflozine in cardiotoxicity treatment. EMPACARD-treatment registry. Six-months follow-up

Congress Presentation

About the speaker

Doctor Andres Jose Daniele

Institute of Oncology Angel H. Roffo, Buenos Aires (Argentina)
0 follower

6 more presentations in this session

Basal characteristics of the prospective spanish immunotherapy registry of cardiovascular toxicity: SIR-CVT

Speaker: Doctor E. Zatarain-Nicolas (Madrid, ES)


The prognostic significance of troponin level in patients with malignancy (NIHR Health Informatics Collaborative TROP-MALIGNANCY study)

Speaker: Doctor A. Kaura (London, GB)


COVID-19 and acute heart failure among patients with cancer

Speaker: Doctor M. Bergami (Bologna, IT)


Effect of 1st line treatment on aortic inflammation as assessed by 18 FDG PET/CT in patients with Hodgkin and non-Hodgkin lymphoma

Speaker: Doctor D. Terentes-Printzios (Athens, GR)


Prognostic impact of coronary artery calcifications in patients with newly diagnosed prostate cancer

Speaker: Doctor N. Stoedkilde-Joergensen (Aarhus, DK)


Access the full session

Cardio-oncology 4

Speakers: Doctor A. Daniele, Doctor E. Zatarain-Nicolas, Doctor A. Kaura, Doctor M. Bergami, Doctor D. Terentes-Printzios...

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb